

Lifevantage Corp  
Form 10-Q  
November 08, 2010

**Table of Contents**

**U.S. SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
Form 10-Q**

**QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010**

**TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_**

**Commission file number 000-30489  
LIFEVANTAGE CORPORATION.**

(Exact name of Registrant as specified in its charter)

COLORADO

90-0224471

(State or other jurisdiction of  
incorporation or organization)

(IRS Employer Identification No.)

11545 W. Bernardo Court, Suite 301, San Diego, California 92127

(Address of principal executive offices)

(858) 312-8000

(Registrant's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Edgar Filing: Lifevantage Corp - Form 10-Q

The number of shares outstanding of the issuer's common stock, par value \$0.001 per share, as of November 4, 2010 was 71,314,323.

---

**Table of Contents**

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

Certain statements contained in this report and the information incorporated by reference herein may contain forward-looking statements (as such term is defined in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended). These statements, which involve risks and uncertainties, reflect our current expectations, intentions, or strategies regarding our possible future results of operations, performance, and achievements. Forward-looking statements include, without limitation: statements regarding future products or product development; statements regarding future selling, general and administrative costs and research and development spending; statements regarding our product development strategy; statements regarding the future performance of our network marketing sales channel; and statements regarding future financial performance, results of operations, capital expenditures and sufficiency of capital resources to fund our operating requirements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable rules of the Securities and Exchange Commission and common law.

These forward-looking statements may be identified in this report and the information incorporated by reference by words such as anticipate, believe, could, estimate, expect, intend, plan, predict, project, should and expressions, including references to assumptions and strategies. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, these statements are subject to certain risks, uncertainties, and contingencies, which could cause our actual results, performance, or achievements to differ materially from those expressed in, or implied by, such statements.

The following factors are among those that may cause actual results to differ materially from our forward-looking statements:

Limited operating history in new business model;

Our ability to successfully expand our operations and manage our future growth;

Difficulty in managing growth and expansion;

Dilutive effects of any potential need to raise additional capital;

The deterioration of global economic conditions and the decline of consumer confidence and spending;

Material weaknesses reported in our internal control over financial reporting;

Environmental liabilities stemming from past operations and property ownership;

Significant dependence upon a single product;

Competition in the dietary supplement market;

The potential failure or unintended negative consequences of our network marketing sales channel;

Our ability to retain independent distributors or to hire new independent distributors on an ongoing basis;

The potential for government or third party actions against us resulting from independent distributor activities that violate applicable laws or regulations;

The potential for third party and governmental actions involving our network marketing sales channel;

Our ability to protect our intellectual property rights and the value of our product;

Our ability to continue to innovate and provide products that are useful to consumers;

2

---

**Table of Contents**

The effect of current and future government regulations of the network marketing and dietary supplement industries on our business;

The effect of unfavorable publicity on our business;

The potential for product liability claims against us;

Our dependence on third party manufacturers to manufacture our product;

The ability to obtain raw material for our product;

Our common stock is currently classified as a penny stock;

Our stock price may experience future volatility;

The illiquidity of our common stock;

Substantial sales of shares of our common stock;

Other factors not specifically described above, including the other risks, uncertainties, and contingencies described under **Description of Business** , **Risk Factors** and **Management's Discussion and Analysis of Financial Condition and Results of Operation** in Items 1 and 7 of our Annual Report on Form 10-K for the year ended June 30, 2010.

When considering these forward-looking statements, you should keep in mind the cautionary statements in this report and the documents incorporated by reference. We have no obligation and do not undertake to update or revise any such forward-looking statements to reflect events or circumstances after the date of this report.

LIFEVANTAGE CORPORATION  
INDEX

	PAGE
<u>PART I. Financial Information</u>	
<u>Item 1. Financial Statements:</u>	
<u>Condensed Consolidated Balance Sheets (unaudited) September 30, 2010 and June 30, 2010</u>	5
<u>Condensed Consolidated Statements of Operations (unaudited) For the Three Month Periods Ended September 30, 2010 and 2009</u>	6
<u>Consolidated Statements of Stockholders Deficit and Comprehensive Income (unaudited) For the Three Months Ended September 30, 2010</u>	7
<u>Condensed Consolidated Statements of Cash Flows (unaudited) For the Three Month Periods Ended September 30, 2010 and 2009</u>	8
<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	9
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	20
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	25
<u>Item 4. Controls and Procedures</u>	25
<u>PART II. Other Information</u>	28
<u>Item 1. Legal Proceedings</u>	28
<u>Item 1A. Risk Factors</u>	28
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	28
<u>Item 3. Defaults Upon Senior Securities</u>	28
<u>Item 4. (Removed and Reserved)</u>	28
<u>Item 5. Other Information</u>	28
<u>Item 6. Exhibits</u>	28
<u>Signatures</u>	29
<u>EX-10.1</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	

**Table of Contents****PART I Financial Information****Item 1. Financial Statements**LIFEVANTAGE CORPORATION AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	<b>September 30, 2010</b>	<b>As of, June 30, 2010</b>
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 2,257,060	\$ 1,637,676
Investments, available for sale	340,000	340,000
Accounts receivable, net	450,479	401,597
Inventory	483,893	493,858
Prepaid expenses and deposits	346,941	153,864
Total current assets	3,878,373	3,026,995
Long-term assets		
Investments, available for sale	85,000	85,000
Property and equipment, net	181,057	196,353
Intangible assets, net	2,017,990	2,045,471
Deferred debt offering costs, net	560,085	844,792
Deposits	28,612	28,613
<b>TOTAL ASSETS</b>	<b>\$ 6,751,117</b>	<b>\$ 6,227,224</b>
<b>LIABILITIES AND STOCKHOLDERS DEFICIT</b>		
Current liabilities		
Accounts payable	\$ 734,648	\$ 770,941
Commissions payable	760,906	591,035
Reserve for sales returns	447,434	343,937
Other accrued expenses	1,087,834	809,507
Customer deposits	—	34,797
Revolving line of credit and accrued interest	433,985	433,985
Short-term derivative liabilities	240,019	1,444,331
Short-term convertible debt, net of discount	144,470	702,361
Total current liabilities	3,849,296	5,130,894
Long-term liabilities		
Deferred rent	25,648	27,191
Derivative liabilities	13,770,010	17,123,119
Convertible debt, net of discount	113,588	121,014
Total liabilities	17,758,542	22,402,218
Commitments and contingencies		
Stockholders deficit		
Preferred stock par value \$0.001 per share, 50,000,000 shares authorized, no shares issued or outstanding		



Edgar Filing: Lifevantage Corp - Form 10-Q

Common stock par value \$0.001 per share, 250,000,000 shares authorized and 69,640,724 and 61,494,849 issued and outstanding as of September 30, 2010 and June 30, 2010, respectively	69,641	61,495
Additional paid-in capital	25,915,703	21,457,145
Accumulated deficit	(36,946,664)	(37,661,857)
Accumulated other comprehensive income	(46,105)	(31,777)
Total stockholders deficit	(11,007,425)	(16,174,994)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	\$ 6,751,117	\$ 6,227,224

The accompanying notes are an integral part of these condensed consolidated statements.

5

---

**Table of Contents**

LIFEVANTAGE CORPORATION AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the three months ended September 30,	
	2010	2009
Sales, net	\$ 6,443,349	\$ 1,857,997
Cost of sales	1,020,135	312,974
Gross profit	5,423,214	1,545,023
Operating expenses:		
Sales and marketing	3,410,843	2,012,166
General and administrative	1,507,093	2,381,156
Research and development	109,793	106,892
Depreciation and amortization	50,716	53,298
Total operating expenses	5,078,445	4,553,512
Operating income (loss)	344,769	(3,008,489)
Other income (expense):		
Interest expense	(1,464,623)	(153,701)
Change in fair value of derivative liabilities	1,835,047	6,027,736
Total other income	370,424	5,874,035
Net income	715,193	2,865,546
Net income per share, basic and diluted	\$ 0.01	\$ 0.05
Weighted average shares, basic	63,684,437	55,634,601
Weighted average shares, diluted	89,693,864	61,841,866

The accompanying notes are an integral part of these condensed consolidated statements.

**Table of Contents**

LIFEVANTAGE CORPORATION AND SUBSIDIARIES  
 CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT AND COMPREHENSIVE INCOME  
 (UNAUDITED)

	Common Stock		Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive	Total
	Shares	Amount			Income	
<b>Balances, June 30, 2010</b>	<b>61,494,849</b>	<b>\$ 61,495</b>	<b>\$ 21,457,145</b>	<b>\$ (37,661,857)</b>	<b>\$ (31,777)</b>	<b>\$ (16,174,994)</b>
Conversion of debt to equity	8,145,875	8,146	4,343,401			4,351,547
Options/Warrants issued for services			115,157			115,157
Currency translation adjustment					(14,328)	(14,328)
Net loss				715,193		715,193
Other comprehensive loss						700,865
<b>Balances, September 30, 2010</b>	<b>69,640,724</b>	<b>\$ 69,641</b>	<b>\$ 25,915,703</b>	<b>\$ (36,946,664)</b>	<b>\$ (46,105)</b>	<b>\$ (11,007,425)</b>

**Table of Contents**

LIFEVANTAGE CORPORATION AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	<b>For the three months ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
<b>Cash Flows from Operating Activities:</b>		
Net income	\$ 715,193	\$ 2,865,546
Adjustments to reconcile net loss to net cash used by operating activities:		
Depreciation and amortization	50,716	53,298
Stock based compensation to employees	85,560	438,867
Stock based compensation to non-employees	29,597	363,381
Non-cash interest expense from convertible debentures	1,063,858	103,453
Non-cash interest expense from amortization of deferred offering costs	284,707	16,549
Consulting fees paid in equity		24,900
Change in fair value of derivative liabilities	(1,835,047)	(6,027,736)
Changes in operating assets and liabilities:		
(Increase)/decrease in accounts receivable, net	(48,882)	706,514
Decrease/(increase) in inventory	9,965	(8,635)
(Increase) in prepaid expenses and deposits	(227,874)	(31,807)
(Decrease) in accounts payable	(36,293)	(157,053)
Increase in accrued expenses	550,151	18,245
<b>Net Cash Provided by (Used by) Operating Activities</b>	<b>641,651</b>	<b>(1,634,478)</b>
<b>Cash Flows Provided by Investing Activities:</b>		
Redemption of investments		50,000
(Purchase) of equipment	(4,455)	
(Purchase) of intangible assets	(3,484)	(12,904)
<b>Net Cash Provided by Investing Activities</b>	<b>(7,939)</b>	<b>37,096</b>
<b>Cash Flows from Financing Activities:</b>		
Net proceeds (payments) from revolving line of credit and accrued interest		(1,012)
Principal payments under capital lease obligation		(15,145)
Issuance of common stock and warrants		904,416
Proceeds from note payable		703,822
<b>Net Cash Provided by Financing Activities</b>		<b>1,592,081</b>
<b>Foreign Currency Effect on cash</b>	<b>(14,328)</b>	<b>1,767</b>
<b>Increase (Decrease) in cash and cash equivalents</b>	<b>619,384</b>	<b>(3,534)</b>
Cash and Cash Equivalents beginning of period	1,637,676	608,795
<b>Cash and Cash Equivalents end of period</b>	<b>2,257,060</b>	<b>605,261</b>

**For the three months  
ended September 30,**

	<b>2010</b>	<b>2009</b>
<b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</b>		
Conversion of long-term debt to common stock	\$ 1,629,175	
Conversion of derivative to common stock	\$ 2,722,372	
Warrants issued for private placement fees		\$ 121,535
Write down of deferred offering costs related to conversion of debt	\$ 132,507	
Cash paid for interest expense	\$ 116,058	\$ 23,409
Cash paid for income taxes		

The accompanying notes are an integral part of these condensed consolidated statements.

**Table of Contents**

LIFEVANTAGE CORPORATION AND SUBSIDIARIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THREE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009  
(UNAUDITED)

These unaudited Condensed Consolidated Financial Statements and Notes should be read in conjunction with the audited financial statements and notes of LifeVantage Corporation as of and for the year ended June 30, 2010 included in our annual report on Form 10-K.

**Note 1 Organization and Basis of Presentation:**

The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ( SEC ). In the opinion of the management of LifeVantage Corporation ( LifeVantage or the Company ), these interim Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair presentation of our financial position as of September 30, 2010, and the results of operations for the three month periods ended September 30, 2010 and 2009 and the cash flows for the three month periods ended September 30, 2010 and 2009. Interim results are not necessarily indicative of results for a full year or for any future period. Certain prior period amounts have been reclassified to conform to our current period presentation.

The condensed consolidated financial statements and notes included herein are presented as required by Form 10-Q, and do not contain certain information included in our audited financial statements and notes for the fiscal year ended June 30, 2010 pursuant to the rules and regulations of the SEC. For further information, refer to the financial statements and notes thereto as of and for the year ended June 30, 2010, and included in the Annual report on Form 10-K on file with the SEC.

**Note 2 Summary of Significant Accounting Policies:**

**Consolidation**

The accompanying financial statements include the accounts of the Lifevantage Inc. and our wholly-owned subsidiaries Lifeline Nutraceuticals Corporation ( LNC ), LifeVantage de México, S. de R.L. de C.V. (Limited Liability Company), Importadora LifeVantage, S. de R.L. de C.V. (Limited Liability Company), and Servicios Administrativos para la Importación de Productos Body & Skin, S.C. All inter-company accounts and transactions between the entities have been eliminated in consolidation.

**Translation of Foreign Currency Statements**

We translate the financial statements of our foreign entities by using the current exchange rate. For assets and liabilities, the exchange rate at the balance sheet date is used. For any investment in subsidiaries and retained earnings, the historical exchange rate is used. For revenue, expenses, gains, and losses, an appropriately weighted average exchange rate for the period is used.

**Table of Contents****Use of Estimates**

Management has made a number of estimates and assumptions relating to the reporting of revenues, expenses, assets and liabilities and the disclosure of contingent assets and liabilities to prepare these consolidated financial statements. Actual results could differ from those estimates.

**Fair Value Measurements**

Fair value measurement requirements are embodied in certain accounting standards applied in the preparation of our financial statements. Significant fair value measurements include our embedded derivative liabilities. See Notes 4 and 8 Convertible Debentures and Common Stock and Warrant Offerings for disclosures related to our common stock and warrant financing arrangements. The fair value hierarchy is defined below:

Fair value hierarchy:

- (1) Level 1 inputs are quoted prices in active markets for identical assets and liabilities.
- (2) Level 2 inputs are inputs which include quoted prices for similar assets and liabilities in active markets and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instrument.
- (3) Level 3 inputs are unobservable inputs and significant to the fair value measurement.

The financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The summary of fair values of financial instruments is as follows at September 30, 2010:

Instrument:	Fair value	Carrying Value	Level	Valuation Methodology
Investments	\$ 425,000	\$ 425,000	2	Market price
Derivative warrant liabilities	\$ 9,061,987	\$ 9,061,987	3	Black-Scholes Lattice model
Embedded conversion liability	\$ 4,948,042	\$ 4,948,042	3	

---

**Table of Contents**

The summary of fair values of financial instruments is as follows at June 30, 2010:

Instrument:	Fair value	Carrying Value	Level	Valuation Methodology
Investments	\$ 425,000	\$ 425,000	2	Market price
Derivative warrant liabilities	\$ 10,573,084	\$ 10,573,084	3	Black-Scholes Lattice model
Embedded conversion liability	\$ 7,994,366	\$ 7,994,366	3	

The following represents a reconciliation of the changes in fair value of financial instruments measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended September 30, 2010 and the year ended June 30, 2010:

	<b>September 30, 2010</b>	<b>June 30, 2010</b>
Beginning balance: Derivative liabilities	\$ 18,567,450	\$ 8,429,710
Total (gains) losses	(1,835,047)	(3,101,673)
Adoption of change in accounting principle		3,267,253
Purchases, sales, issuances and settlements, net	(2,722,374)	9,972,160
Ending balance: Derivative liabilities	\$ 14,010,029	\$ 18,567,450

**Cash and Cash Equivalents**

We consider only our monetary liquid assets with original maturities of three months or less as cash and cash equivalents.

**Accounts Receivable**

Accounts receivable at September 30, 2010 consist primarily of credit card receivables including a percentage holdback by the credit card processor. The holdback balance at September 30, 2010 was \$333,338. Based on the Company's verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its direct and independent distributor sales as of September 30, 2010 is not necessary. No bad debt expense has been recorded for the three months ended September 30, 2010 or the year ended June 30, 2010.

**Investments**

In 2008 we invested in auction rate preferred securities of closed-end funds ( ARPS ) to maximize interest income. We have classified these investments as available for sale in the balance sheet.



**Table of Contents****Inventory**

Inventory is stated at the lower of cost or market value. Cost is determined using the first-in, first-out method. We have capitalized payments to our contract product manufacturer for the acquisition of raw materials and commencement of the manufacturing, bottling and labeling of our product. As of September 30, 2010 and June 30, 2010, inventory consisted of:

	September 30, 2010	June 30, 2010
Finished goods	\$ 380,601	\$ 326,095
Raw materials	103,292	167,763
Total inventory	\$ 483,893	\$ 493,858

**Deferred Offering Costs**

Deferred offering costs consist of cash paid to and the fair value of warrants issued to placement agents in conjunction with our convertible debenture financings. Amortization of these costs commence upon the closing date and continue for the life of the convertible debenture instruments.

As of September 30, 2010 and June 30, 2010, deferred offering costs consisted of:

	September 30, 2010	June 30, 2010
Deferred offering costs	\$ 1,370,212	\$ 1,370,212
Amortization of deferred offering costs	(810,127)	(525,420)
Deferred offering costs, net	\$ 560,085	\$ 844,792

**Revenue Recognition**

We ship the majority of our product directly to the consumer via UPS and receive substantially all payment for these sales in the form of credit card charges. Revenue from direct product sales to customers is recognized upon passage of title and risk of loss to customers when product is shipped from the fulfillment facility. Sales revenue and estimated returns are recorded when product is shipped. Our return policy is to provide a 30-day money back guarantee on orders placed by customers. After 30 days, we do not issue refunds to direct sales customers for returned product. In the network marketing sales channel, we allow terminating distributors to return unopened unexpired product that they have purchased within the prior twelve months, subject to certain consumption limitations. To date, returns from terminating distributors have been negligible. We have experienced overall monthly returns of approximately 3% of sales. Our return rate for sales directly to consumers, which excludes sales through our network marketing channel is approximately 1% of sales based on historical experience and our return rate for sales through our network marketing channel is approximately 4% of sales based upon our historical experience and network marketing industry experience. As of September 30, 2010 and June 30, 2010, our reserve balance for returns and allowances was \$447,434 and \$343,937, respectively.

**Table of Contents****Income/(Loss) per share**

Basic income or loss per share is computed by dividing the net income or loss by the weighted average number of common shares outstanding during the period. Diluted earnings per common share are computed by dividing net income by the weighted average common shares and potentially dilutive common share equivalents. For the three month period ended September 30, 2010 the effects of approximately 3.5 million common shares issuable pursuant to options granted through our 2007 Long-Term Incentive Plan are not included in computations because their effect was anti-dilutive. For the three month period ended September 30, 2009 the effects of approximately 5.5 million common shares issuable pursuant to the convertible debentures and warrants issued in our private placement offerings, compensation based warrants issued and options granted through our 2007 Long-Term Incentive Plan are not included in computations because their effect was anti-dilutive.

**Segment Information**

Our operations are aggregated into a single reportable operating segment based upon similar economic and operating characteristics as well as similar markets. Our operations are also subject to similar regulatory environments. We conduct our operations in the U.S., Japan and Mexico. Substantially all long-lived assets are located in the U.S. Revenues by geographic area are as follows:

	<b>Three months ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
Revenues from unaffiliated customers		
U.S. operations	\$ 5,148,078	\$ 1,857,997
Japan operations	1,241,331	
Mexico operations	53,940	
Total revenues	\$ 6,443,349	\$ 1,857,997

**Research and Development Costs**

We expense all costs related to research and development activities as incurred. Research and development expenses for the three month periods ended September 30, 2010 and 2009 were \$109,793 and \$106,892, respectively.

**Shipping and Handling**

Shipping and handling costs associated with inbound freight and freight out to customers, including independent distributors, are included in cost of sales. Shipping and handling fees charged to all customers are included in sales.

**Table of Contents**

**Stock-Based Compensation**

In certain circumstances, we issued common stock for invoiced services and in other similar situations to pay contractors and vendors. Payments in equity instruments to non-employees for goods or services are accounted for using the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued.

**Derivative Financial Instruments**

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. However, we have entered into certain other financial instruments and contracts, such as freestanding warrants and embedded conversion features on convertible debt instruments that are not afforded equity classification. These instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements.

Derivative financial instruments consist of financial instruments or other contracts that contain a notional amount and one or more underlying variables (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets.

We estimate fair values of derivative financial instruments using various techniques that are considered to be consistent with the objective measurement of fair values. In selecting the appropriate technique, we consider, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as freestanding warrants, we generally use the Black Scholes Merton option valuation technique, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, and risk free rates) necessary to fair value these instruments. For embedded conversion features we generally use a lattice technique because it contains all the requisite assumptions to value these features. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock. Since derivative financial instruments are initially and subsequently carried at fair values, our income or loss will reflect the volatility in changes to these estimates and assumptions.

**Convertible Debt Instruments**

We issued convertible debt in September and October 2007, November and December 2009 and January and February 2010. We review the terms of convertible debt and equity instruments that we issue to determine whether there are embedded derivative instruments, including the embedded conversion options that are required to be bifurcated and accounted for separately as derivative instrument liabilities. Also, in connection with the sale of convertible debt and equity instruments, we may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. For option-based derivative financial instruments, we use the Black-Scholes option pricing model to value the derivative instruments. For embedded conversion derivatives we use a lattice model to value the derivative.

**Table of Contents**

When the embedded conversion option in a convertible debt instrument is not required to be bifurcated and accounted for separately as a derivative instrument, we review the terms of the instrument to determine whether it is necessary to record a beneficial conversion feature. When the effective conversion rate of the instrument at the time it is issued is less than the fair value of the common stock into which it is convertible, we recognize a beneficial conversion feature, which is credited to equity and reduces the initial carrying value of the instrument.

When convertible debt is initially recorded at less than its face value as a result of allocating some or all of the proceeds received to derivative instrument liabilities, to a beneficial conversion feature or to other instruments, the discount from the face amount, together with the stated interest on the convertible debt, is amortized over the life of the instrument through periodic charges to income, using the effective interest method.

**Income Taxes**

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. As of September 30, 2010 we have determined that we do not have an income tax liability and we have a full valuation allowance booked against our tax asset.

Effective January 1, 2009, we account for any uncertainty in income taxes by recognizing the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. We measure the tax benefits recognized in the financial statements from such a position based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The application of income tax law is inherently complex. As such, we are required to make certain subjective assumptions and judgments regarding income tax exposures. The result of the reassessment of our tax positions did not have an impact on the consolidated financial statements.

**Concentration of Credit Risk**

We disclose significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and investments. At September 30, 2010, we had \$1,988,040 in cash accounts at one financial institution, approximately \$114,346 in foreign bank accounts and \$154,674 in an investment management account at another financial institution.

**Effect of New Accounting Pronouncements**

We have reviewed recently issued, but not yet effective, accounting pronouncements and do not believe any such pronouncements will have a material impact on our financial statements.

**Table of Contents**

**Note 3 Investments**

In 2008 we invested in auction rate preferred securities of closed-end funds ( ARPS ) to maximize interest income. We considered investments in these instruments as available for sale in accordance with relevant accounting guidance.

ARPS have historically have been liquid but have been adversely affected by the broader national liquidity crisis. We entered into an agreement with our investment advisor, Stifel Nicolaus, to repurchase 100% of the remaining ARPS at par on or prior to June 30, 2012. The schedule for repurchase of remaining ARPS by Stifel Nicolaus over the next three years is as follows:

- (a) The greater of 10 percent or \$25,000 to be completed by June 30, 2011;
- (b) The balance of outstanding ARPS, if any, to be repurchased by June 30, 2012.

We have established a line of credit to borrow against 80% of these investments so that sales of these securities would not have to occur in order to fund our operating needs. The interest on amounts borrowed has been approximately the same as the interest being earned from the underlying securities. Management classified 80% or \$340,000 of our investments as short term. The remaining 20% or \$85,000 of our investments that may not be available in the current year are classified as long-term.

As of September 30, 2010, in light of the plan for repurchase and the repurchases made during the year, management has determined that there has not been a change in the fair value of the securities owned. We have not recorded any impairment related to these investments, as management does not believe that the underlying credit quality of the assets has been impacted by the reduced liquidity of these investments. In addition, no unrealized gain or loss has been recorded on these assets. We consider the inputs to valuation of these securities as level 2 inputs in the fair value hierarchy.

**Note 4 Convertible Debentures**

**2007**

On September 26, 2007 and October 31, 2007, we issued convertible debentures in a private placement offering that bear interest at 8 percent per annum and have a term of three years. The convertible debentures are convertible into common stock at \$0.20 per share during their term and at maturity, at our option, may be repaid in full or converted into common stock at the lower of \$0.20 per share or the average trading price for the 10 days immediately prior to the maturity date on September 26, 2010 and October 31, 2010. We intend to convert the remaining debentures upon maturity. We also issued warrants to purchase shares of our common stock at \$0.30 per share in the private placement offering. We allocated the proceeds received in the private placement to the convertible debentures and warrants to purchase common stock based on their relative estimated fair values. The discount from the face amount of the convertible debentures represented by the value initially assigned to any associated warrants and derivative liabilities is amortized over the period to the due date of each convertible debenture, using the effective interest method. We redeemed all warrants issued in the offering in fiscal 2009. As of September 30, 2010 all amounts are classified as current and all amounts are due in fiscal 2011.

**Table of Contents**

Details of the issuances are in the table below:

<b>Date Issued</b>	<b>Face</b>		<b>Face Value Converted</b>	<b>Discount Converted</b>	<b>Discount</b>	<b>Net Value</b>
	<b>Value Issued</b>	<b>Debt Discount</b>			<b>Amortized at September 30, 2010</b>	<b>at September 30, 2010</b>
September 26, 2007	\$ 1,075,000	\$ (937,510)	\$ (1,075,000)	\$ 242,173	\$ 695,337	\$
October 31, 2007	415,000	(378,235)	(255,000)	139,624	223,081	144,470
<b>Totals</b>	<b>\$ 1,490,000</b>	<b>\$ (1,315,745)</b>	<b>\$ (1,330,000)</b>	<b>\$ 381,797</b>	<b>\$ 918,418</b>	<b>\$ 144,470</b>

As of September 30, 2010 the convertible debentures are convertible into 800,000 shares with a value as of September 30, 2010 of \$400,000 which exceeds the principal value by \$240,000.

We determined that the conversion option in the convertible debentures did not satisfy the definition of being indexed to our own stock, as an anti-dilution provision in the convertible debentures reduces the conversion price dollar for dollar if we issue common stock with a price lower than the conversion price of the convertible debentures. Based on authoritative guidance effective on July 1, 2009 the embedded conversion option in the convertible debentures was a liability as of July 1, 2009. We have bifurcated the embedded conversion option from the host contract and accounted for this feature as a separate derivative liability. As of September 30, 2010 the embedded conversion option estimated to be \$240,019 is reflected in short-term derivative liabilities on the accompanying consolidated balance sheet.

In addition, we have reviewed the terms of the convertible debentures to determine whether there are any other embedded derivative instruments that may be required to be bifurcated and accounted for separately as derivative instrument liabilities and have determined that either they did not meet the criteria or were immaterial in amount.

Effective interest associated with the convertible debentures totaled \$224,052 and \$103,453 for the three months ended September 30, 2010 and 2009, respectively. Effective interest is accreted to the balance of convertible debt until maturity. Simple interest paid totaled \$16,943 and \$23,409 for the three months ended September 30, 2010 and 2009, respectively. A total of \$256,568 was paid for commissions and expenses incurred in the 2007 private placement offering which is being amortized into interest expenses over the term of the convertible debentures on a straight-line basis. As of September 30, 2010 we have recorded accumulated amortization of 2007 deferred offering costs of \$230,734.

**2009 and 2010**

Between November 2009 and February 2010, we issued convertible debentures with an aggregate principal amount of \$4,995,000 that bear interest at 8 percent per annum and have a term of two years. Accordingly, as of September 30, 2010, these amounts are recorded as long-term convertible debt on the accompanying balance sheet. We received aggregate net cash proceeds of \$4,035,687, after deducting placement fees of \$464,313 and taking into account the conversion of an outstanding note payable as described below. The convertible debentures are convertible into common stock at \$0.20 per share during their term. Subject to meeting certain equity conditions, we have the option to redeem the outstanding principal plus accrued interest for cash at any time during the term of the debentures. In conjunction with these convertible debentures we issued warrants to purchase an aggregate of 14,997,449 shares common stock with an exercise price of \$0.50 per share and warrants to purchase an

**Table of Contents**

aggregate of 2,035,860 shares of common stock with an exercise price of \$0.20 per share. In addition, a note payable to a related party in the amount of \$500,000 was converted to a convertible debenture. We allocated the proceeds received in the private placements to the embedded derivative and warrants based on their estimated fair values.

Details of the issuances are in the table below:

<b>Date Issued</b>	<b>Face</b>		<b>Face Value Converted</b>	<b>Discount Converted</b>	<b>Discount</b>	<b>Net Value</b>
	<b>Value Issued</b>	<b>Debt Discount</b>			<b>Amortized at September 30, 2010</b>	<b>at September 30, 2010</b>
November 18, 2009	\$ 246,896	\$ (246,896)	\$ (159,840)	\$ 158,705	\$ 3,528	\$ 2,393
December 11, 2009	874,125	(874,125)	(199,800)	198,354	18,050	16,604
December 31, 2009	254,745	(254,745)			7,164	7,164
January 20, 2010	1,255,743	(1,255,743)	(259,740)	257,547	35,473	33,280
February 4, 2010	1,849,149	(1,849,149)	(499,600)	497,126	42,267	39,793
February 25, 2010	514,342	(514,342)	(94,915)	94,008	15,261	14,354
<b>Totals</b>	<b>\$ 4,995,000</b>	<b>\$ (4,995,000)</b>	<b>\$ (1,213,895)</b>	<b>\$ 1,205,740</b>	<b>\$ 121,743</b>	<b>\$ 113,588</b>

As of September 30, 2010 the convertible debentures are convertible into an aggregate of 18,905,525 shares with a value as of September 30, 2010 of \$9,452,762 which exceeds the principal value by \$5,671,657.

Based on authoritative guidance effective on July 1, 2009 we have concluded that the embedded conversion option in the convertible debentures is required to be bifurcated from the host contract and accounted for this feature as a separate derivative liability, at fair value, in our financial statements. In addition, we determined that the warrants issued in conjunction with the convertible debentures are required to be carried as derivative liabilities, at fair value, in our financial statements, due to certain anti-dilution provisions. At of September 30, 2010, the embedded conversion option is estimated to be \$4,708,023 and the warrant derivative is estimated to be \$2,505,245 and both are recorded in long-term liabilities.

In addition, we have reviewed the terms of the convertible debentures to determine whether there are any other embedded derivative instruments that may be required to be bifurcated and accounted for separately as derivative instrument liabilities and have determined that either they did not meet the criteria or were immaterial in amount.

Effective interest associated with the convertible debentures totaled \$953,768 for the three month period ended September 30, 2010. Effective interest is accreted to the balance of convertible debt until maturity. Simple interest paid was \$97,019 for the three month period ended September 30, 2010. We incurred an aggregate of \$1,138,660 in commissions and expenses in connection with the 2009 private placement offerings, \$464,313 of which was paid in cash and the balance of which was reflected in the issuance of warrants with a fair market value of \$674,347. The \$1,138,660 in commissions and expenses is being amortized into interest expense over the term of the convertible debentures. As of September 30, 2010 we have recorded accumulated amortization of deferred offering costs of \$579,393.

**Note 5 Line of Credit**

We established a line of credit to borrow up to 80% of our investments. As of September 30, 2010, we can borrow up to \$600,000. The line is collateralized by our auction rate securities. The interest rate charged through September 30, 2010, 3.00 percent, is 0.25 percentage points below the published Wall Street Journal Prime Rate, which was 3.25% percent as of September 30, 2010. At September 30, 2010, we have borrowed approximately \$433,985, including accrued interest, from the line.

**Table of Contents**

**Note 6 Stockholders Equity**

During the three months ended September 30, 2010 we issued 8,145,875 shares of common stock as a result of conversions of convertible debentures.

Our Articles of Incorporation authorize the issuance of preferred shares. However, as of September 30, 2010, none have been issued nor have any rights or preferences been assigned to the preferred shares by our Board of Directors.

**Note 7 Stock-based Compensation**

We adopted and the shareholders approved the 2007 Long-Term Incentive Plan (the Plan ), effective November 21, 2006, to provide incentives to certain eligible employees who are expected to contribute significantly to our strategic and long-term performance objectives and growth. A maximum of 10,000,000 shares of our common stock can be issued under the Plan in connection with the grant of awards. Awards to purchase common stock have been granted pursuant to the Plan and are outstanding to various employees, officers, directors, independent distributors and Scientific Advisory Board ( SAB ) members at prices between \$0.21 and \$0.76 per share, vesting over one- to three-year periods. Awards expire in accordance with the terms of each award and the shares subject to the award are added back to the Plan upon expiration of the award. As of September 30, 2010, awards for the purchase of an aggregate of 8,473,731 shares of our common stock are outstanding.

Payments in equity instruments for goods or services are accounted for under the guidance of share based payments, which require use of the fair value method. We have adjusted the expense for the anticipated forfeitures. Compensation based options totaling 58,000 and 756,000 were granted for the three month periods ended September 30, 2010 and 2009, respectively.

For the three months ended September 30, 2010, stock based compensation of \$115,157 was reflected as an increase to additional paid in capital. Of the stock based compensation for the three months ended September 30, 2010, \$85,560 was employee related and \$29,597 was non-employee related. For the three months ended September 30, 2009 stock based compensation of \$802,248 was reflected as an increase to additional paid in capital. Of the stock based compensation for the three months ended September 30, 2009, \$438,867 was employee related and \$363,381 was non-employee related.

Compensation expense was calculated using the fair value method during the three month periods ended September 30, 2010 and 2009 using the Black-Scholes option pricing model. The following assumptions were used for options and warrants granted during the three month periods ended September 30, 2010 and 2009:

1. risk-free interest rates of between 1.33 and 1.62 percent for the three months ended September 30, 2010 and 3.52 percent for the three months ended September 30, 2009;
2. dividend yield of -0- percent;
3. expected life of 3 to 6 years; and
4. a volatility factor of the expected market price of our common stock of between 128 and 129 percent for the three months ended September 30, 2010 and 337 percent for the three months ended September 30, 2009.



**Table of Contents**

**Note 8 Contingencies and Litigation**

**Note 9 Subsequent Events**

On October 31, 2010 we issued an aggregate of 800,000 shares of our common stock as a result of the conversion of our remaining outstanding October 31, 2007 convertible debentures.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis contains forward-looking statements within the meaning of the federal securities laws. We urge you to carefully review our description and examples of forward-looking statements included in the section entitled "Cautionary Note Regarding Forward-Looking Statements" at the beginning of this report. Forward-looking statements speak only as of the date of this report and we undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this report. Actual events or results may differ materially from such statements. In evaluating such statements, we urge you to specifically consider various factors identified in this report, including the matters set forth below in Part II, Item 1A of this report, any of which could cause actual results to differ materially from those indicated by such forward-looking statements. The following discussion and analysis should be read in conjunction with the accompanying financial statements and related notes, as well as the Financial Statements and related notes in our Annual report on Form 10-K for the fiscal year ended June 30, 2010 and the risk factors discussed therein.*

**Overview**

This management's discussion and analysis reviews the financial condition and results of operations of LifeVantage Corporation (the Company, LifeVantage, or we, us or our) and its wholly-owned subsidiaries Lifeline Nutraceutical Corporation (LNC), LifeVantage de México, S. de R.L. de C.V. (Limited Liability Company), Importadora LifeVantage, S. de R.L. de C.V. (Limited Liability Company), and Servicios Administrativos para la Importación de Productos Body & Skin, S.C.

We are a dietary supplement company that manufactures, markets, distributes, and sells Protandim, a patented dietary supplement intended to increase the body's natural antioxidant protection by inducing multiple protective enzymes including superoxide dismutase (SOD) and catalase (CAT) through network marketing and direct-to-consumer sales channels. We also sell our LifeVantage TrueScience Anti-Aging Cream, a skin care product, through the same channel.

Our revenue depends significantly upon the number and productivity of our independent distributors. Independent distributors market and sell our products and recruit new distributors based on the distinguishing benefits and innovative characteristics of our products. We have developed a distributor compensation plan and other incentives designed to motivate our independent distributors to market and sell our products and to build sales organizations. If we experience delays or difficulties in introducing compelling products or attractive initiatives to independent distributors, this can have a negative impact on our revenue and harm our business.

**Table of Contents**

We primarily sell a single product, Protandim, and in June 2009 we began selling our LifeVantage TrueScience Anti-Aging Cream ( LifeVantage TrueScience ) which incorporates the ingredients in Protandim and other proprietary ingredients. We developed Protandim, a proprietary blend of ingredients that combats oxidative stress by increasing the body's natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective antioxidant enzymes including SOD, CAT, and glutathione synthase.

We sell Protandim and LifeVantage TrueScience through our network marketing sales channel utilizing independent distributors and directly to individuals through our preferred customer program.

To date, we have focused our research efforts on investigating various aspects and consequences of the imbalance of oxidants and antioxidants, an abnormality, which is a central underlying feature in many disorders. We intend to continue our research, development, and documentation of the efficacy of Protandim to provide credibility to the market. We also anticipate undertaking research, development, testing, and licensing efforts to be able to introduce additional products in the future, although we may not be successful in this endeavor.

Ongoing research and development projects involving Protandim are currently in various stages of completion with several institutions including the University of Colorado at Denver Health Science Center, University of Minnesota's Masonic Cancer Center, Ohio State University, University Hospital in Brno, Czech Republic, University of Michigan and Louisiana State University. The studies relate to various conditions including pulmonary hypertension, non-alcoholic fatty liver disease, Duchenne muscular dystrophy, coronary artery bypass graft failure, renal failure, diabetes, and photoaging of the skin. The recently completed and published peer-reviewed mouse study at Louisiana State University found a significant increase in the expression levels of SOD and catalase enzymes and tumor incidence and multiplicity were reduced in mice fed a Protandim® diet by 33% and 57%, respectively, compared with mice on a basal diet. Another study, conducted by a prominent dermatologist using Protandim®, is examining the relationship between anti-aging and the skin's natural ability to rejuvenate at the cellular level.

Net revenue from Protandim®, TrueScience® and related marketing materials totaled \$6,443,349 for the three months ended September 30, 2010, and \$1,857,997 for the three months ended September 30, 2009, respectively.

**Three Months Ended September 30, 2010 Compared to Three Months Ended September 30, 2009**

Revenue We generated net revenue of \$6,443,349 during the three months ended September 30, 2010, and generated net revenue of \$1,857,997 during the three months ended September 30, 2009. The increase in revenue is due to continuing growth in our network marketing channels in the U.S. and Japan with no substantial change in Mexico sales.

Gross Margin Our gross profit percentage for the three month periods ended September 30, 2010 and 2009 was 84% and 83%, respectively. The higher gross margin in 2010 was primarily due to continuing focus on efficiencies and cost reduction measures. We believe that our margin should be fairly stable in this range, however, as we increase sales into our international markets and/or change the mix of our product offerings, the margin could vary.

**Table of Contents**

**Operating Expenses** Total operating expenses for the three months ended September 30, 2010 were \$5,078,445 as compared to operating expenses of \$4,553,512 for the three months ended September 30, 2009. Operating expenses consist of sales and marketing expenses, general and administrative expenses, research and development, and depreciation and amortization expenses. Operating expenses increased primarily due to increased commissions for distributors, which was offset by decreases in costs associated with headcount and stock-based compensation.

**Sales and Marketing Expenses** Sales and marketing expense increased from \$2,012,166 for the three months ended September 30, 2009 to \$3,410,843 for the three months ended September 30, 2010. This increase was due primarily to commissions paid to distributors due to the higher sales volume and other expenses related to sales incentives and our entry into the Japan market.

**General and Administrative Expenses** Our general and administrative expense decreased from \$2,381,156 for the three months ended September 30, 2009 to \$1,507,093 for the three months ended September 30, 2010. The decrease for the three months ended September 30, 2010 was due primarily to decreased costs associated with headcount and decreased legal fees. This decrease was partially offset by increased bonus accruals, professional fees and benefit costs.

**Research and Development** Our research and development expenses decreased from \$106,892 for the three months ended September 30, 2009 to \$109,793 for the three months ended September 30, 2010. The decrease was primarily a result of decreased lab fees paid to the University of Colorado.

**Depreciation and Amortization Expense** Depreciation and amortization expense decreased from \$53,298 during the three months ended September 30, 2009 to \$50,716 during the three months ended September 30, 2010. The decrease was due to assets becoming fully depreciated in the quarter.

**Net Other Income and Expense** We recognized net other income of \$370,424 during the three months ended September 30, 2010 as compared to net other income of \$5,874,035 during the three months ended September 30, 2009. These fluctuations between periods are primarily the result of a decrease in the gain recognized due to the change in fair value of the derivative liabilities during the three months ended September 30, 2010 of \$4,192,689 as compared to the three months ended September 30, 2009, as well as an increase in interest expense recognized of \$1,310,922 for the three months ended September 30, 2010 as compared to the three months ended September 30, 2009.

**Net Income/Loss** We recorded net income of \$715,193 for the three month period ended September 30, 2010 compared to net income of \$2,865,546 for the three month period ended September 30 2009. The decrease in net income of \$2,150,353 for the three months ended September 30, 2010 as compared to the three months ended September 30, 2009 is due to a decrease of \$5,503,611 in other income offset by an increase in operating income of \$3,353,258.

**Liquidity and Capital Resources**

Our primary liquidity and capital resource requirements are to finance the cost of our planned sales and marketing efforts, the manufacture and sale of Protandim and our LifeVantage TrueScience Anti-Aging Skin Cream, and to pay our general and administrative expenses. Our primary sources of liquidity are cash flow generated from the sales of our product and funds raised from our 2009 private placement financing transactions which closed in 2009 and 2010.

**Table of Contents**

At September 30, 2010, our available liquidity was approximately \$2,257,060, including available cash and cash equivalents. This represented an increase of \$619,384 from the \$1,637,676 in cash and cash equivalents at June 30, 2010. During the three months ended September 30, 2010, our net cash provided by operating activities was \$641,651 as compared to net cash used by operating activities of \$1,634,478 during the three months ended September 30, 2009.

During the three months ended September 30, 2010, our net cash used by investing activities was \$7,939 due to purchases of intangible and fixed assets. During the three months ended September 30, 2009, our net cash provided by investing activities was \$37,096 primarily due to the redemption of investments offset by the purchase of equipment.

We did not have any cash provided by financing activities during the three months ended September 30, 2010 compared to \$1,592,081 during the three months ended September 30, 2009. Cash provided from financing activities during the three months ended September 30, 2009 was related to proceeds from the issuance of common stock and warrants and notes payable from related parties.

We maintain an investment portfolio that is managed by a professional financial institution. This portfolio of auction rate private securities, or ARPS, of AA and AAA rated closed-end funds, which historically have been extremely liquid, has been adversely affected by the broader national liquidity crisis. We have negotiated a repurchases plan with the financial institution holding these securities.

We have a line of credit secured by our securities, which allows us to borrow up to 80% of the value of these securities. Based upon that line of credit, management has classified 80% or \$340,000 of our investments as short term. The remaining 20% or \$85,000 of our investment that may not be available in the current year is classified as long-term. However, future economic events could change the portions of these classified as short term and long term.

At September 30, 2010, we had working capital (current assets minus current liabilities) of \$29,077 compared to negative working capital of \$(2,103,899) at June 30, 2010. The increase in working capital was primarily due to being cash flow positive during the quarter and the reduction of the current derivative liabilities.

We intend to convert our remaining short-term debentures and related derivative liabilities into 800,000 shares of our common stock during the second quarter of our fiscal 2011. These conversions should have a further positive effect on our working capital. Based on our forecasted cash flow for fiscal 2011 we have determined that cash on hand will be sufficient to fund our operations through September 30, 2011 and the foreseeable future thereafter.

**Off-Balance Sheet Arrangements**

As of September 30, 2010, we did not have any off-balance sheet arrangements.

**Critical Accounting Policies**

We prepare our financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments, and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates. Our significant accounting policies are described in Note 2 to our financial statements. Certain of these significant accounting policies require us to make difficult, subjective, or complex judgments or estimates. We consider an accounting estimate to be critical if (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

**Table of Contents**

There are other items within our financial statements that require estimation, but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. Management has discussed the development and selection of these critical accounting estimates with our board of directors, and the audit committee has reviewed the foregoing disclosure.

**Allowances for Product Returns** We record allowances for product returns at the time we ship the product based on estimated return rates of 1% to 4%. We base these accruals on the historical return rate since the inception of our selling activities, and the specific historical return patterns of the product.

We offer a 30-day, money back unconditional guarantee to all direct customers. As of September 30, 2010, our September 2010 direct and network marketing sales shipments of approximately \$2,270,000 were subject to the money back guarantee. We replace product returned due to damage during shipment wholly at our cost, the total of which historically has been negligible. In addition, we allow terminating distributors to return 30% of unopened unexpired product that they purchased during the prior twelve months, subject to certain consumption limitations.

We monitor our return estimate on an ongoing basis and may revise the allowances to reflect our experience. Our allowance for product returns was \$447,434 on September 30, 2010, compared with a \$343,900 on June 30, 2010. To date, product expiration dates have not played any role in product returns, and we do not expect product expiration dates to affect product returns in the foreseeable future because it is unlikely that we will ship product with an expiration date earlier than the latest allowable product return date.

**Inventory Valuation** We state inventories at the lower of cost or market on a first-in first-out basis. From time to time we maintain a reserve for inventory obsolescence and we base this reserve on assumptions about current and future product demand, inventory whose shelf life has expired and market conditions. From time to time, we may be required to make additional reserves in the event there is a change in any of these variables. We recorded a reserve for obsolete inventory as of September 30, 2010 of approximately \$48,000 related to certain marketing materials held in inventory.

**Revenue Recognition** We ship the majority of our product directly to the consumer through the direct to consumer and network marketing sales channels via United Parcel Service, ( UPS ), and receive substantially all payment for these shipments in the form of credit card charges. We recognize revenue from direct product sales to customers upon passage of title and risk of loss to customers when product is shipped from the fulfillment facility. Sales revenue and estimated returns are recorded when product is shipped.

**Derivative Instruments** In connection with the sale of debt or equity instruments, we may sell options or warrants to purchase our common stock. In certain circumstances, these options or warrants may be classified as derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may contain embedded derivative instruments, such as conversion options, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative instrument liability.

**Table of Contents**

The identification of, and accounting for, derivative instruments is complex. For options, warrants and any bifurcated conversion options that are accounted for as derivative instrument liabilities, we determine the fair value of these instruments using the Black-Scholes option pricing model. That model requires assumptions related to the remaining term of the instruments and risk-free rates of return, our current common stock price and expected dividend yield, and the expected volatility of our common stock price over the life of the instruments. Because of the limited trading history for our common stock, we have estimated the future volatility of our common stock price based on not only the history of our stock price but also the experience of other entities considered comparable to us. The identification of, and accounting for, derivative instruments and the assumptions used to value them can significantly affect our financial statements.

**Intangible Assets** **Patent Costs** We review the carrying value of our patent costs and compare to fair value at least annually to determine whether the patents have continuing value. In determining fair value, we consider undiscounted future cash flows and market capitalization.

**Stock-Based Compensation** We use the fair value approach to account for stock-based compensation in accordance with the modified version of prospective application.

**Research and Development Costs** We have expensed all of our payments related to research and development activities.

**Recently Issued Accounting Standards**

We have reviewed recently issued, but not yet effective, accounting pronouncements and do not believe any such pronouncements will have a material impact on our financial statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Under the rules and regulations of the SEC, as a smaller reporting company we are not required to provide the information required by this Item.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

As of September 30, 2010, we conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. The term disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2010 at the reasonable assurance level due to the material weaknesses in our internal control over financial reporting discussed immediately below.

**Table of Contents**

**Identified Material Weaknesses**

A material weakness is a control deficiency, or combination of deficiencies, that results in more than a remote likelihood that a material misstatement of our financial statements would not be prevented or detected on a timely basis by our employees in the normal course of performing their assigned functions. Management identified material weaknesses during our assessment of our internal control over financial reporting as of September 30, 2010. In particular, we concluded that we did not maintain:

1. Adequate oversight of certain accounting functions and did not maintain adequate documentation of management review and approval of accounting transactions and financial reporting processes; and
2. Formal policies governing certain accounting transactions and financial reporting processes.

In conclusion, our Chief Executive Officer and Chief Financial Officer determined that we did not maintain effective internal control over financial reporting as of September 30, 2010.

**Management's Remediation Initiatives**

We are in the process of evaluating our material weaknesses. We have already begun to remediate many of the material weaknesses. In an effort to remediate the identified material weaknesses and other deficiencies and to enhance our internal control over financial reporting, we have initiated, or plan to initiate, the following series of measures:

- 1) Implement appropriate management oversight and approval activities; and
- 2) Establish comprehensive formal general accounting policies and procedures and require employees to sign off such policies and procedures as documentation of their understanding of and compliance with company policies.

We plan to test our updated controls and remediate our material weaknesses by June 30, 2011.

In our Annual Report on Form 10-K for the year ended June 30, 2010 (filed with the SEC on September 15, 2010) in addition to the material weaknesses discussed above, we identified two other material weaknesses in our internal controls related to the lack of: (i) sufficient personnel with an appropriate level of accounting knowledge, experience and training in the selection and application of technical accounting principles in accordance with GAAP to support our financial accounting and reporting functions; and (ii) a whistleblower hotline. During the quarter ended September 30, 2010 we hired additional staff with experience managing and working in the corporate accounting department of a publicly traded company and established a whistleblower hotline.

**Conclusion**

The above identified material weaknesses resulted in material audit adjustments to our 2010 financial statements. If the identified material weaknesses are not remediated, one or more of the identified material weaknesses noted above could result in a material misstatement in our reported financial statements in a future interim or annual period.

**Table of Contents**

In light of the identified material weaknesses, management performed (1) significant additional substantive review of those areas described above, and (2) additional analyses, including but not limited to a detailed balance sheet and statement of operations analytical review that compared changes from the prior period's financial statements and analyzed all significant differences. These procedures were completed so management could gain assurance that the financial statements included in this report fairly present in all material respects our financial position, results of operations and cash flows for the periods presented.

**Changes in Internal Control over Financial Reporting**

During the quarter ended September 30, 2010, we implemented the following changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act; we hired additional staff and established a whistleblower hotline.



**Table of Contents**

**PART II Other Information**

**Item 1. Legal Proceedings**

None.

**Item 1A. Risk Factors**

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I. Item 1A Risk Factors in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010. The risks and uncertainties described in such risk factors and elsewhere in this report have the potential to materially affect our business, financial condition, results of operations, cash flows, projected results and future prospects. As of the date of this report, we do not believe that there have been any material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Information required by Item 701 of Regulation S-K as to equity securities we sold during the period covered by this report that were not registered under the Securities Act of 1933 has been previously reported (as such term is defined in Rule 12b-2 of the Securities Exchange Act of 1934).

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. (Removed and Reserved)**

**Item 5. Other Information**

None.

**Item 6. Exhibits**

See the exhibit index immediately following the signature page of this report.

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LIFEVANTAGE CORPORATION

Date: November 8, 2010

*/s/ David W. Brown*  
David W. Brown  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: November 8, 2010

*/s/ Carrie E. McQueen*  
Carrie E. McQueen  
Chief Financial Officer  
(Principal Financial Officer)  
29

---

**Table of Contents**

**Exhibit Index**

Exhibit	Description
10.1#	LifeVantage FY2011 Corporate Bonus Plan
31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a)
31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a)
32.1**	Certification of principal executive officer and principal financial officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	Certification of principal executive officer and principal financial officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
**	This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing
#	Management contract or compensatory plan